Skip to main content
Skip to main navigation
Search for :
Product Development Strategy
Early Clinical Development
Phase I/IIa Clinical Trials
Phase II/III Clinical Trials
Interventional Phase IIIb/Phase IV Clinical Trials
Observational Research & Registries
Product Launch & Management
Market Access Solutions
Strategic Sales Outsourcing
Biopharmaceutical Sales & Marketing
Healthcare Payers & Providers
Medical Device & Diagnostics
Public Health & Government
Small to Mid-Sized Biopharma
Specialty Clinical Associations and Patient Organizations
Central Nervous System
Diabetes & Endocrinology
Early Phase Oncology
Public Health Interest
Other Therapeutic Areas
Ethics & Compliance
Build brand value by promoting effective health management
In the face of healthcare complexity, knowledge is power. The more you educate your audiences about your product, the higher your chances of success.
Clinical Educator Programs
Quintiles has a solution to help deliver the critical information pharma provides and doctors and patients need.
Read fact sheet
Overcome accessibility issues and limited resources to deliver ongoing education to healthcare professionals and encourage better adherence among patients.
Read case study
A Patient Centric Focus
In this article explains how a patient-centric focus can be used to support delivery of brand strategy, innovative sales and marketing solutions, and market entry models.
Payers are gaining a greater voice, and proving evidence of value starts with patient education.
Dedicated clinical educators can help improve patient outcomes – and build your brand.
To increase patient adherence, we worked with over 600,000 diabetes patients and clinicians.
Understanding real-world patients is the key to more effective market access programs.
Find out more
Quintiles Recognized as Industry Leader in Phase II/III Research for Second Year in a Row
Quintiles’ First Quarter 2014 Earnings Call Scheduled for Thursday, May 1st
Quintiles Appoints Dr. Stella Blackburn to Lead Global Risk Management
The Collaboration Mandate
Partnerships, Patients and Proof
Biomarkers: Recent Advances in their Application to the Treatment of Hematologic Malignancies